miR-34 targets key oncogenic factors like c-Met and influences the expression of CSC markers, such as CD44 and CD133, thereby inhibiting tumor formation and enhancing the sensitivity of pancreatic cancer cells to certain chemotherapies [85]. Here, CD44 is linked to familial pancreatic carcinoma.